Singapore Approves Neurophet’s AI Brain Degeneration Analysis Software

South Korean health technology company Neurophet has obtained certification from the Singapore Health Sciences Authority for its AI-enabled degenerative brain disease diagnostic support software.

Its flagship software, Neurophet Aqua, analyzes brain MRI using AI to check for brain atrophy and white matter degeneration, as seen in neurodegenerative diseases such as Alzheimer’s disease and vascular dementia. The company claims that its product can segment and analyze brain images in five minutes with a 0% analysis failure rate.

WHY IS IT IMPORTANT

Neurophet is looking to enter the highly valuable Singaporean medical industry, which is expected to grow to around $49 billion by 2029. The company first entered the market with the Neurophet Scale PET, which quantitatively analyzes biomarkers of Alzheimer’s disease by combining PET and MRI brain images. . It also received HSA approval for this end of last year.

THE GREAT TREND

The company is working twice as hard to further penetrate the Southeast Asian market by collaborating with the Dementia Research Center of the Lee Kong Chian School of Medicine at Nanyang Technological University in Singapore to conduct research research on brain diseases that will validate its AI software offerings.

In December, the company partnered with a medical device distributor Clairvo Technologies to expand access to Neurophet Aqua in the Japanese market.